Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.9
Journals
JCM
Special Issues
Atherosclerosis: Current Challenges and New Perspectives
share announcement

Atherosclerosis: Current Challenges and New Perspectives

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (25 August 2023) | Viewed by 2105

Special Issue Editor

Prof. Dr. Naqiong Wu

E-Mail Website
Guest Editor
Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Interests: strategies of lipid-lowering therapy; residual cardiovascular risk; intravascular ultrasound; optical coherence tomography; plaque stabilization and regression; coronary calcification; calcified aortic valve stenosis

Special Issue Information

Dear Colleagues,

Atherosclerotic cardiovascular disease (ASCVD) is currently the number one disease threatening human health and life in the world, both in developed and developing countries. With the studies and clinical transformations of the mechanisms of atherosclerosis, the strategies of prevention and treatment of this kind of disease are constantly being enriched. However, the incidence of several risk factors related to atherosclerosis, especially hypertension, diabetes, and hyperlipidemia, is still rising, leading to severe challenges in the prevention and control of ASCVD. At the same time, the residual risk of ASCVD deserves further investigation. This Special Issue focuses on the current challenges of atherosclerosis and the prospects for its future prevention and treatment. All contributions are welcome. This Special Issue will include clinical studies about new treatment-target or new lipid-lowering therapy (cohort study, observational study, or randomized control study), basic studies about mechanisms of atherosclerosis, especially about residual risk (lipid-related residual risk, inflammation etc.).

Prof. Dr. Naqiong Wu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atherosclerotic cardiovascular disease (ASCVD)
  • new treatment-target
  • new lipid-lowering therapy
  • lipid-related residual risk
  • inflammation

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1254 KiB  
Article
The FCGR2A Is Associated with the Presence of Atherosclerotic Plaques in the Carotid Arteries—A Case-Control Study
by Anna Szpakowicz, Aleksandra Szum-Jakubowska, Anna Lisowska, Marlena Dubatówka, Andrzej Raczkowski, Marcin Czajkowski, Łukasz Szczerbiński, Małgorzata Chlabicz, Adam Krętowski and Karol Adam Kamiński
J. Clin. Med. 2023, 12(20), 6480; https://doi.org/10.3390/jcm12206480 - 12 Oct 2023
Cited by 1 | Viewed by 779
Abstract
Background. Atherosclerotic plaques in carotid arteries (APCA) are a prevalent condition with severe potential complications. Studies continuously search for innovative biomarkers for APCA, including those participating in cellular metabolic processes, cell adhesion, immune response, and complement activation. This study aimed to assess the [...] Read more.
Background. Atherosclerotic plaques in carotid arteries (APCA) are a prevalent condition with severe potential complications. Studies continuously search for innovative biomarkers for APCA, including those participating in cellular metabolic processes, cell adhesion, immune response, and complement activation. This study aimed to assess the relationship between APCA presence and a broad range of cardiometabolic biomarkers in the general population. Methods. The study group consisted of consecutive participants of the population study Bialystok PLUS. The proximity extension assay (PEA) technique from the Olink Laboratory (Uppsala, Sweden) was used to measure the levels of 92 cardiometabolic biomarkers. Results. The study comprised 693 participants (mean age 48.78 ± 15.27 years, 43.4% males, N = 301). APCA was identified in 46.2% of the participants (N = 320). Of the 92 biomarkers that were investigated, 54 were found to be significantly linked to the diagnosis of APCA. After adjusting for the traditional risk factors for atherosclerosis in multivariate analysis, the only biomarker that remained significantly associated with APCA was FCGR2A. Conclusion. In the general population, the prevalence of APCA is very high. A range of biomarkers are linked with APCA. Nonetheless, the majority of these associations are explained by traditional risk factors for atherosclerosis. The only biomarker that was independently associated with APCA was the FCGR2A. Full article
(This article belongs to the Special Issue Atherosclerosis: Current Challenges and New Perspectives)
►▼ Show Figures

Figure 1

20 pages, 679 KiB  
Article
Missed Opportunities in Implementation and Optimization of Lipid-Lowering Therapies in Very-High-Risk Patients Presenting with ST-Segment Elevation Myocardial Infarction
by Kristen Kopp, Lukas Motloch, Alexander Berezin, Victoria Maringgele, Halyna Ostapenko, Moritz Mirna, Lukas Schmutzler, Anna Dieplinger, Uta C. Hoppe and Michael Lichtenauer
J. Clin. Med. 2023, 12(17), 5685; https://doi.org/10.3390/jcm12175685 - 31 Aug 2023
Viewed by 1000
Abstract
The aim of this retrospective study was to provide real-world data on lipid-lowering therapy (LLT) implementation and low-density lipoprotein cholesterol (LDL-C) target achievement in an ST-segment elevation myocardial infarction (STEMI) population, with a focus on very-high-risk patients according to European guidelines criteria. Methods: [...] Read more.
The aim of this retrospective study was to provide real-world data on lipid-lowering therapy (LLT) implementation and low-density lipoprotein cholesterol (LDL-C) target achievement in an ST-segment elevation myocardial infarction (STEMI) population, with a focus on very-high-risk patients according to European guidelines criteria. Methods: Included were all STEMI patients with available LDL-C and total cholesterol treated at a large tertiary center in Salzburg, Austria, 2018–2020 (n = 910), with stratification into very-high-risk cohorts. Analysis was descriptive, with variables reported as number, percentages, median, and interquartile range. Results: Among patients with prior LLT use, statin monotherapy predominated, 5.3% were using high-intensity statins, 1.2% were using combined ezetimibe therapy, and none were taking PCSK9 inhibitors at the time of STEMI. In very-high-risk secondary prevention cohorts, LLT optimization was alarmingly low: 8–22% of patients were taking high-intensity statins, just 0–6% combined with ezetimibe. Depending on the very-high-risk cohort, 27–45% of secondary prevention patients and 58–73% of primary prevention patients were not taking any LLTs, although 19–60% were actively taking/prescribed medications for hypertension and/or diabetes mellitus. Corresponding LDL-C target achievement in all very-high-risk cohorts was poor: <22% of patients had LDL-C values < 55 mg/dL at the time of STEMI. Conclusion: Severe shortcomings in LLT implementation and optimization, and LDL-C target achievement, were observed in the total STEMI population and across all very-high-risk cohorts, attributable in part to deficits in care delivery. Full article
(This article belongs to the Special Issue Atherosclerosis: Current Challenges and New Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop